Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunotherapy in Parkinson’s Disease: Micromanaging Alpha-Synuclein Aggregation
Sonia George, Patrik Brundin
Journal of Parkinson s Disease (2015) Vol. 5, Iss. 3, pp. 413-424
Open Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

Parkinson disease
Werner Poewe, Klaus Seppi, Caroline M. Tanner, et al.
Nature Reviews Disease Primers (2017) Vol. 3, Iss. 1
Closed Access | Times Cited: 3800
Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments
Panchanan Maiti, Jayeeta Manna, Gary Dunbar
Translational Neurodegeneration (2017) Vol. 6, Iss. 1
Open Access | Times Cited: 449
The Role of Microglia in Retinal Neurodegeneration: Alzheimer's Disease, Parkinson, and Glaucoma
Ana I. Ramı́rez, Rosa de Hoz, Elena Salobrar‐García, et al.
Frontiers in Aging Neuroscience (2017) Vol. 9
Open Access | Times Cited: 397
α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease
Cecilia S. Lindestam Arlehamn, Rekha Dhanwani, John Pham, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 320
Therapeutic approaches to target alpha-synuclein pathology
Patrik Brundin, Kuldip D. Dave, Jeffrey H. Kordower
Experimental Neurology (2017) Vol. 298, pp. 225-235
Open Access | Times Cited: 218
Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson’s disease
Sonia George, Nolwen L. Rey, Trevor Tyson, et al.
Molecular Neurodegeneration (2019) Vol. 14, Iss. 1
Open Access | Times Cited: 196
Precision medicine for disease modification in Parkinson disease
Alberto J. Espay, Patrik Brundin, Anthony E. Lang
Nature Reviews Neurology (2017) Vol. 13, Iss. 2, pp. 119-126
Closed Access | Times Cited: 160
Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models
Andreas Weihofen, Yuting Liu, Joseph W. Arndt, et al.
Neurobiology of Disease (2018) Vol. 124, pp. 276-288
Open Access | Times Cited: 159
Intercellular Spread of Protein Aggregates in Neurodegenerative Disease
Albert A. Davis, Cheryl E. G. Leyns, David M. Holtzman
Annual Review of Cell and Developmental Biology (2018) Vol. 34, Iss. 1, pp. 545-568
Open Access | Times Cited: 119
Emerging Treatment Approaches for Parkinson’s Disease
Thomas B. Stoker, Kelli Torsney, Roger A. Barker
Frontiers in Neuroscience (2018) Vol. 12
Open Access | Times Cited: 112
Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy
Shunsuke Koga, Dennis W. Dickson
Journal of Neurology Neurosurgery & Psychiatry (2017) Vol. 89, Iss. 2, pp. 175-184
Closed Access | Times Cited: 109
Alteration of the fecal microbiota in North-Eastern Han Chinese population with sporadic Parkinson’s disease
Fang Li, Peng Wang, Zhu Chen, et al.
Neuroscience Letters (2019) Vol. 707, pp. 134297-134297
Closed Access | Times Cited: 88
Sorting out release, uptake and processing of alpha‐synuclein during prion‐like spread of pathology
Trevor Tyson, Jennifer A. Steiner, Patrik Brundin
Journal of Neurochemistry (2015) Vol. 139, Iss. S1, pp. 275-289
Open Access | Times Cited: 86
Delivery of immunoglobulin G antibodies to the rat nervous system following intranasal administration: Distribution, dose-response, and mechanisms of delivery
Niyanta N. Kumar, Jeffrey J. Lochhead, Michelle E. Pizzo, et al.
Journal of Controlled Release (2018) Vol. 286, pp. 467-484
Open Access | Times Cited: 82
Nanobodies raised against monomeric ɑ-synuclein inhibit fibril formation and destabilize toxic oligomeric species
Marija Iljina, Liu Hong, Mathew H. Horrocks, et al.
BMC Biology (2017) Vol. 15, Iss. 1
Open Access | Times Cited: 66
Microglia-targeting nanotherapeutics for neurodegenerative diseases
Nanxia Zhao, Nicola L. Francis, Hannah Calvelli, et al.
APL Bioengineering (2020) Vol. 4, Iss. 3
Open Access | Times Cited: 66
How strong is the evidence that Parkinson's disease is a prion disorder?
Patrik Brundin, Jiyan Ma, Jeffrey H. Kordower
Current Opinion in Neurology (2016) Vol. 29, Iss. 4, pp. 459-466
Open Access | Times Cited: 65
Peripheral-Central Neuroimmune Crosstalk in Parkinson's Disease: What Do Patients and Animal Models Tell Us?
Marie‐Thérèse Armentero, Silvia Cerri, Fabio Blandini
Frontiers in Neurology (2019) Vol. 10
Open Access | Times Cited: 61
Drug Discovery and Development Targeting Dementia
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 151-151
Open Access | Times Cited: 20
Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson’s disease etiology
Simon G. Coetzee, Steven Pierce, Patrik Brundin, et al.
Scientific Reports (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 52
α-Synuclein increases β-amyloid secretion by promoting β-/γ-secretase processing of APP
Hazel Hall‐Roberts, Bernard L. Schneider, David R. Brown
PLoS ONE (2017) Vol. 12, Iss. 2, pp. e0171925-e0171925
Open Access | Times Cited: 50
Current surgical treatments for Parkinson's disease and potential therapeutic targets
DarrinJ Lee, RobertF Dallapiazza, Philippe De Vloo, et al.
Neural Regeneration Research (2018) Vol. 13, Iss. 8, pp. 1342-1342
Open Access | Times Cited: 50
Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches
Niyanta N. Kumar, Michelle E. Pizzo, Geetika Nehra, et al.
Bioconjugate Chemistry (2018) Vol. 29, Iss. 12, pp. 3937-3966
Open Access | Times Cited: 50
Treating Parkinson’s Disease with Antibodies: Previous Studies and Future Directions
Anne-Marie Castonguay, Claude Gravel, Martin Lévesque
Journal of Parkinson s Disease (2020) Vol. 11, Iss. 1, pp. 71-92
Open Access | Times Cited: 41
Gut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease
Jing Liu, Fei Xu, Zhiyan Nie, et al.
Frontiers in Cellular and Infection Microbiology (2020) Vol. 10
Open Access | Times Cited: 39
Page 1 - Next Page

Scroll to top